Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis

American Journal of Ophthalmology

Volumn 150, Issue 1, 2010, Pages

  Macejko, Thomas T ^a   Bergmann, Mark T ^b   Williams, Jon I ^c   Gow, James A ^c   Gomes, Paul J ^d   McNamara, Timothy R ^c   Abelson, Mark B ^d,e,f  

^a Greater Cincinnati Inc   (United States)

^b Center for Orthopedic Care   (United States)

^c ISTA Pharmaceuticals Inc   (United States)

^d Ora Inc   (United States)

^e SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETOTASTINE; EYE DROPS; PLACEBO;

ADULT; ALLERGIC CONJUNCTIVITIS; ALLERGY TEST; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONJUNCTIVAL ALLERGEN CHALLENGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRY EYE; EYE IRRITATION; EYE PAIN; FEMALE; FOOT FRACTURE; HEADACHE; HUMAN; KERATITIS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIGRAINE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; OCULAR PRURITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 77953911802     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.02.007     Document Type: Article

References (23)

1. Abelson M.B., Smith L., and Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocul Surf 1 3 (2003) 127-149
2. von Mutius E., Martinez F.D., Fritzsch C., Nicolai T., Roell G., and Thiemann H.H. Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med 149 2 pt 1 (1994) 358-364
3. Abelson M.B., George M.A., and Garofalo C. Differential diagnosis of ocular allergic disorders. Ann Allergy 70 2 (1993) 95-109
4. Katelaris C.H. Allergic rhinoconjunctivitis-an overview. Acta Ophthalmol Scand 230 suppl (2000) 66-68
5. Ono S.J., and Abelson M.B. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 115 1 (2005) 118-122
6. Bonini S., Bonini S., Vecchione A., Naim D.M., Allansmith M.R., and Balsano F. Inflammatory changes in conjunctival scrapings after allergen provocation in humans. J Allergy Clin Immunol 82 3 pt 1 (1988) 462-469
7. Barnes P.J. Pathophysiology of allergic inflammation. In: Adkinson Jr. N.F., Bochner B.S., Busse W.W., Holgate S.T., Lemanske Jr. R.F., and Simons F.E. (Eds). Middleton's Allergy: Principles & Practice. 7th ed. (2009), Elsevier Mosby, Philadelphia 455-472
8. Simons F.E., and Simons K.J. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 330 23 (1994) 1663-1670
9. Simons F.E. Advances in H1-antihistamines. N Engl J Med 351 21 (2004) 2203-2217
10. Kato M., Nishida A., and Aga Y. Pharmacokinetic and pharmacodynamic evaluation of the central effect of the novel antiallergic agent bepotastine besilate. Arzneimittelforschung 47 10 (1997) 1116-1124
11. Sakai A., Kikuchi M., Yato N., Kikkawa S., Saito N., and Narita H. Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung 47 8 (1997) 954-958
12. Kaminuma O., Ogawa K., Kikkawa H., Kikuchi M., Naito K., and Ikezawa K. A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol Pharm Bull 21 4 (1998) 411-413
13. Ishibashi Y., Harada S., and Niimura M. Long term treatment of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese]. J Clin Ther Med 13 5 (1997) 1337-1359
14. Ishibashi Y., Harada S., Niimura M., Kawashima M., Yamamoto S., and Yoshida H. Clinical evaluation of TAU-284 (betotastine besilate) on eczema/dermatitis, prurigo, and pruritus cutaneous [in Japanese]. J Clin Ther Med 13 5 (1997) 1383-1400
15. Baba S., Takasaki T., Baba K., et al. Late phase II clinical study of TAU-284 for perennial allergic rhinitis-dose finding study by the double-blind method [in Japanese]. J Clin Ther Med 13 5 (1997) 1259-1286
16. Abelson M.B., Torkildsen G.L., Williams J.I., Gow J.A., Gomes P.J., and McNamara T.R. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 31 9 (2009) 1908-1921
17. Abelson M.B. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 81 3 (1998) 211-218
18. Shulman D.G., Amdahl L., Washington C., and Graves A. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clin Ther 25 4 (2003) 1096-1106
19. Reigelman R.K. Studying a study and testing a test (2005), Lippincott Williams & Wilkins, Philadelphia 336
20. Abelson M.B., and Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 125 6 (1998) 797-804
21. Abelson M.B., Chapin M.J., Kapik B.M., and Shams N.B. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch Ophthalmol 121 5 (2003) 626-630
22. Abelson M.B., Gomes P., Crampton H.J., Schiffman R.M., Bradford R.R., and Whitcup S.M. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 26 1 (2004) 35-47
23. Abelson M.B., Chambers W.A., and Smith L.M. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 108 1 (1990) 84-88